StockNews.AI
MXCT
StockNews.AI
49 days

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

1. PHCbi signed an exclusive deal to distribute MaxCyte's ExPERT platform in Japan. 2. Exclusive agreements may enhance MXCT's market presence in Asia.

2m saved
Insight
Article

FAQ

Why Bullish?

This agreement can expand MXCT's revenue potential in Japan, similar to past agreements that boosted stock prices.

How important is it?

The distribution deal opens new market opportunities, likely influencing MXCT's stock performance positively.

Why Short Term?

Initial positive market reactions can be expected soon following the announcement, as seen in similar deals.

Related Companies

PHCHDSCMD
TOKYO--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan. In Singapore, SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, separately entered into an exclusive distri.

Related News